Epidemiology, risk factors, and lifestyle modifications for gout

被引:200
作者
Saag, Kenneth G. [1 ]
Choi, Hyon
机构
[1] Univ Alabama Birmingham, UAB Ctr Educ & Res Therapeut Musculoskeletal Diso, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[2] Harvard Univ, Sch Med, Womens Hosp, Boston, MA USA
[3] Univ British Columbia, Mary PAck Arthrit Soc Chair Rheumatol, Div Rheumatol, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1186/ar1907
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gout affects more than 1% of adults in the USA, and it is the most common form of inflammatory arthritis among men. Accumulating data support an increase in the prevalence of gout that is potentially attributable to recent shifts in diet and lifestyle, improved medical care, and increased longevity. There are both nonmodifiable and modifiable risk factors for hyperuricemia and gout. Nonmodifiable risk factors include age and sex. Gout prevalence increases in direct association with age; the increased longevity of populations in industrialized nations may contribute to a higher prevalence of gout through the disorder's association with aging-related diseases such as metabolic syndrome and hypertension, and treatments for these diseases such as thiazide diuretics for hypertension. Although gout is considered to be primarily a male disease, there is a more equal sex distribution among elderly patients. Modifiable risk factors for gout include obesity, the use of certain medications, high purine intake, and consumption of purine-rich alcoholic beverages. The increasing prevalence of gout worldwide indicates that there is an urgent need for improved efforts to identify patients with hyperuricemia early in the disease process, before the clinical manifestations of gout become apparent.
引用
收藏
页数:7
相关论文
共 63 条
[1]   Hyperuricemia and gout in renal transplant recipients [J].
Abdelrahman, M ;
Rafi, A ;
Ghacha, R ;
Youmbissi, JT ;
Qayyum, T ;
Karkar, A .
RENAL FAILURE, 2002, 24 (03) :361-367
[2]  
Adams P F, 1999, Vital Health Stat 10, P1
[3]  
*AM HEART ASS, 2003, HEART DIS STROK STAT
[4]  
Arromdee E, 2002, J RHEUMATOL, V29, P2403
[5]   Initial treatment of hypertension [J].
August, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :610-617
[6]  
Baroletti Steven, 2004, Prog Transplant, V14, P143
[7]   EFFECT OF ASCORBIC-ACID ON URIC-ACID EXCRETION WITH A COMMENTARY ON RENAL HANDLING OF ASCORBIC-ACID [J].
BERGER, L ;
GERSON, CD ;
YU, TF .
AMERICAN JOURNAL OF MEDICINE, 1977, 62 (01) :71-76
[8]   TUBULAR DYSFUNCTION FOLLOWING KIDNEY-TRANSPLANTATION [J].
BETTER, OS .
NEPHRON, 1980, 25 (05) :209-213
[9]   On the brink of novel therapeutic options for an ancient disease [J].
Bieber, JD ;
Terkeltaub, RA .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2400-2414
[10]   HYPERURICEMIA AND GOUT AMONG HEART-TRANSPLANT RECIPIENTS RECEIVING CYCLOSPORINE [J].
BURACK, DA ;
GRIFFITH, BP ;
THOMPSON, ME ;
KAHL, LE .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 (02) :141-146